This is a cross-sectional cohort study of metastatic GastroIntestinal Stromal Tumor (GIST) patients on imatinib for ≥ 10 years included in EORTC trial 62005-STBSG entitled "Phase 3 randomized, intergroup, international tiral assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) expressing the KIT receptor tyrosine kinase (CD117) - NCT00685828". With this study, the aim is to identify patient characteristics, tumour characteristics, treatment factors and quality of life outcomes associated with prolonged treatment with imatinib and/or prolonged survival. This observational study will further help to put in place a questionnaire to evaluate patients quality of life with prolonged imatinib treatment, that will then be used in a prospective study.
Study Type
OBSERVATIONAL
No intervention
Patient characteristics
Age at time of randomization, gender, medical history and previous treatment(s)
Time frame: At time of registration
Tumour characteristics
Stage of the disease, tumor grade, tumor location and molecular features of primary tumor
Time frame: At time of registration
Duration of imatinib treatment
Time on imatinib treatment from start untill definitive discontinuation of imatinib treatment
Time frame: At time of registration
Health releated quality of life
QLQ-C30
Time frame: At time of registration
Overall survival
From time of randomization to the date of death, whatever the cause
Time frame: At time of registration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.